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E-mail address: hyx@shsmu.edu.cn (Y. Hu).This work studied the role of cyclic AMP responsive element binding protein (CREB) in the up-reg-
ulation of M1 muscarinic acetylcholine receptor (M1 receptor) density by sarsasapogenin (ZMS) in
CHO cells transfected with M1 receptor gene (CHOm1 cells). During cell aging, sarsasapogenin ele-
vated M1 receptor density as well as CREB and phosphor-CREB (pCREB) levels. CREB peaked earliest,
followed by pCREB and M1 receptor density peaked last. When CREB synthesis was blocked by anti-
sense oligonucleotides, the elevation effect of sarsasapogenin on M1 receptor density was abolished.
These results suggest that sarsasapogenin up-regulates M1 receptor density in aged cells by promot-
ing CREB production and phosphorylation. Furthermore, the results support the hypothesis that
pCREB regulates M1 receptor gene expression through heterodimer formation.
 2010 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Memory formation requires transcription and translation of
new mRNAs, among which those mediated by the transcription
factor cyclic AMP responsive element binding protein (CREB) are
thought to be prime candidates. Conkright et al. [1] performed an
analysis of CREB target genes and identiﬁed approximately 70
putative candidates, ﬁnding that many of them were important
for neuronal speciﬁcation, axon guidance, synapse formation, and
neurotransmitter release [2]. Postnatal disruption of CREB leads
to progressive neurodegeneration [3], whereas elevation of CREB
protein levels by somatic cell gene transfer attenuates the long-
term memory impairment that is associated with normal agingchemical Societies. Published by E
t binding protein; CRE, cyclic
BP, CREB-binding protein; M
ceptor, muscarinic receptor
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ium dodecyl sulfate; PVDF,
BDNF, brain derived neuro-
se; MAPK,mitogen-activated[4]. In order for CREB to activate transcription, CREB must be phos-
phorylated [5], resulting in the active form phosphor-CREB
(pCREB), which then binds to the cyclic AMP responsive element
(CRE) of target genes as well as to an adaptor protein (or mediator)
known as CREB-binding protein (CBP) that, in turn, contacts and
activates the basal transcriptional apparatus [6].
The relationship between CREB phosphorylation and musca-
rinic acetylcholine receptor (M receptor) expression is far from
fully understood. It has been reported [7,8] that the regulatory ele-
ments of the muscarinic receptor subtype 1 (M1 receptor) gene lo-
cated at the promoter region lacked the CRE sequence (TGACGTCA)
but contained the activator protein-1 (AP-1) binding element se-
quence (TGACTCA). Since CREB and AP-1 can form hetero-dimers
to activate the transcription of target genes [9,10], it is reasonable
to propose that the phosphorylation of CREB may enhance M1
receptor expression. However, this hypothesis needs to be proven
by experimental results.
Sarsasapogenin (ZMS), is an active ingredient in Rhizoma ane-
marrhenae, a medicinal herb frequently used in traditional Chinese
medicine to treat certain chronic diseases including Alzheimer’s
disease and other memory deﬁcits associated with aging. Its chem-
ical structure is 5b, 20a, 22a, 25S-spirostan-3b-ol. Previous
research has demonstrated that ZMS is neither a cholinesteraselsevier B.V. All rights reserved.
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cline of M receptor density in brains and improve the memory of
aged rats and certain neurodegeneration models [11]. The purpose
of this research was to determine whether CREB plays a role in the
regulatory action of ZMS on M1 receptor density, and furthermore
how it might do this; neither of these issues has not been studied
previously. We ﬁrst examined the effect of ZMS on CREB/pCREB
expression and M1 receptor density in CHO cells that were trans-
fected with the M1 receptor gene. We then compared the time
courses of the ratios of CREB, pCREB and M1 receptor density in
ZMS and dimethylsulfoxide (DMSO) treated groups. Finally, we
examined whether ZMS could still up-regulate the M1 receptor
density when CREB expression was blocked by speciﬁc antisense
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Fig. 1. Effect of ZMS on CREB and pCREB expression in CHOm1 cells. (A) Western
blot showing CREB and pCREB in extracts of cells treated with ZMS/DMSO or DMSO
alone. (B and C) Results of two-way ANOVA for CREB and pCREB expression in ZMS/
DMSO or DMSO control-treated groups. Data were expressed as the mean ± S.E.M
(the respective bands of the DMSO-treated group at 0 h were set as 0). The F value
and P value between treatments were indicated in the ﬁgure.2. Materials and methods
2.1. Cell culture and treatment
The CHO cells transfected with M1 receptor gene (CHOm1 cell
line) was generously provided by Professor Buckley from Univer-
sity College London, and cells were subsequently cultured follow-
ing his protocol [12]. In brief, the cells were sub-cultured in
Dulbecco’s modiﬁed Eagle’s medium containing proline. The cells
stopped growing at 90% conﬂuence and the M receptor density be-
gan to decrease due to cell aging. At this point, ZMS (2  103 M in
DMSO, Sigma, 98% purity) was added to a ﬁnal concentration of
105 M, and samples were examined for M1 receptor density and
CREB/pCREB content after 12 h, 24 h, 48 h, 72 h and 96 h.
2.2. Western blot of CREB and pCREB
Sodium dodecyl sulfate (SDS)-lysed cells were separated on
SDS–polyacrylamide gels. The proteins were transferred to a poly-
vinylidene diﬂuoride (PVDF) membrane, blocked in skim milk, and
incubated overnight at 4 C in primary antibody (rabbit anti-CREB
antibody, 1:200, Santa Cruz, or mouse anti-pCREB antibody,
1:1000, Upsate, or anti-b-actin antibody, 1:1000, Santa Cruz),
which after washing was then followed by incubation in secondary
antibody and ﬁnally colour-development with ECL reagents
(Pierce). Densitometric quantiﬁcation was performed with an im-
age analyzer (Gel Doc 2000, Bio-Rad). The gray values were ulti-
mately normalised to b-actin.
2.3. Transfection of CHOm1 cells with antisense oligonucleotides of
CREB
The antisense oligonucleotide for CREB 50-TGGTCATCTAGT-
CACCGGTG-30 [13] was synthesised by Shanghai Sangon
Biotechnology. It matches as the reverse complement of nucleo-
tides 27–46 (GenBank accession no. X14788 [GenBank]). The sense
sequence 50-CACCGGTGACTAGATGACCA-30 showed no signiﬁcant
match and thus served as a non-functional control. Transfection
was carried out using the Fugene 6 Transfection Reagent kit (Roche)
following instructions in the kit protocol. In brief, when the cells
were 70% conﬂuent, 1lg of oligonucleotides and 3 ll transfection
reagent were added to 105 cells in 1 ml culture medium and were
then incubated for 4 h to complete the transfection. CREB, pCREB
and M1 receptor density were examined 48 h later.
2.4. 3H-QNB binding assay for M receptor density
M receptor density was measured using the 3H-QNB single
point method, as modiﬁed by Hu et al. [11]. Non-speciﬁc binding
was measured with a parallel assay containing atropine. Given thatthe M receptor in CHOm1 cells were exclusively subtype 1, the spe-
ciﬁc binding of 3H-QNB represented the M1 receptor density.
2.5. Statistical analysis
The data are presented as mean ± S.E.M. Statistical analysis was
carried out using the SAS software package. Two-way ANOVA with
post hoc Newman–Keuls test was used for experiments involving
treatment and time of more than two groups. Paired Student’s t-
tests were used for comparisons between two experimental
groups. P < 0.05 was considered as signiﬁcant.
3. Results
3.1. ZMS increases CREB and pCREB expression in CHOm1 cells
As shown in Fig. 1A, Western blotting revealed that CREB and
pCREB were both signiﬁcantly elevated by ZMS. The differences
between ZMS treatment and DMSO solvent control were highly
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(Fig. 1C).
3.2. ZMS raises M1 receptor density in CHOm1 cells
As shown in Fig. 2, the M1 receptor density in CHOm1 cells
dropped over time due to cell aging. At 24 h after the addition of
ZMS/DMSO, when the M1 receptor densities were at their peak val-
ues, there was no signiﬁcant difference between ZMS and DMSO
treatments. After that point, the M1 receptor density in the DMSO
group dropped more rapidly than in the ZMS group, resulting in
F = 61.81, P < 0.0001.
3.3. Different kinetics of ZMS-induced elevation of CREB, pCREB and
M1 receptor density
The ratios of CREB, pCREB and M1 receptor density in the ZMS
vs. DMSO-treated cells at each time point were calculated and
plotted against time (taking the ratio at 0 h as 1). The peak value
appeared earliest for CREB (12 h or earlier), followed by pCREB
(12–24 h), and ﬁnally the M1 receptor density which appeared
much later (more than 48 h later) (Fig. 3).
3.4. CREB antisense oligonucleotide abolishes the elevation effect of
ZMS on M1 receptor density
Western blotting showed that, as compared to the non-func-
tional sense oligonucleotide, the antisense oligonucleotide0
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Fig. 2. Effect of ZMS/DMSO and DMSO control treatment on M1 receptor density in
CHOm1 cells. Data of M1 receptor densities were expressed as the mean ± S.E.M,
n = 4 for each treatment at each time point. F and P values between treatments
using a two-way ANOVA are indicated in the ﬁgure.
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Fig. 3. Time courses of the ratios of CREB (d), pCREB (j) and M1 receptor density
() in the ZMS/DMSO and DMSO control-treated groups. Data were expressed with
the ratios at 0 h as 1.0. Signiﬁcance indicators * and ** indicate P < 0.05 and P < 0.01,
respectively, when compared to the ratio of the 0 h group by t-test.
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Fig. 4. Effect of the antisense CREB oligonucleotide on the expression of CREB and
pCREB. (A) Western blotting bands showing the relative intensities of different
groups. (B) Densitometric analysis showing that the ratios of pCREB to CREB were
not signiﬁcantly decreased by the CREB antisense oligonucleotide. Data are shown
as mean ± S.E.M, n = 4. NS indicates not signiﬁcant by paired t-test. The average
ratios were shown on the top of each column. (C) Mean ± S.E.M of M1 receptor
density, n = 6, ** indicates P < 0.01 and NS indicates not signiﬁcant by paired t-test.decreased the intensities of both the CREB and pCREB bands signif-
icantly in both the DMSO or ZMS-treated groups (Fig. 4A). How-
ever, the antisense oligonucleotide did not block CREB
phosphorylation, and thus no signiﬁcant decrease in the pCREB/
CREB ratios could be detected (Fig. 4B). In contrast, the antisense
oligonucleotide induced a decrease in M1 receptor density in both
groups, and abolished the elevation effect of ZMS (Fig. 4C).
4. Discussion
The main purpose of this research was to explore the role of
CREB in the up-regulation of M1 receptor density by ZMS. The re-
sults showed that when ZMS increased M1 receptor density in aged
CHOm1 cells, the intracellular levels of CREB and pCREB were also
elevated. The peak of CREB appeared ﬁrst, followed by pCREB, and
ﬁnally that of M1 receptor density. When the CREB synthesis was
blocked by its antisense oligonucleotide, the elevation effect of
ZMS on M1 receptor density was abolished. Taken together, these
results reveal that the up-regulation of M1 receptor density in aged
cells by ZMS involves increases in levels of both CREB and pCREB.
The activation of CREB involves two steps: the production of a
sufﬁcient amount of CREB and the phosphorylation of CREB
(Ser133 is the most important phosphorylation site). Many of the
1552 H. Hu et al. / FEBS Letters 584 (2010) 1549–1552previous ﬁndings came from observations of CREB phosphorylation
as well as from the blocking of phosphorylation [14]. In this paper,
we found that ZMS had a positive effect on CREB levels, which
could be blocked by CREB antisense oligonucleotide. The advantage
of blocking with the antisense is its high speciﬁcity based on the
matching of paired bases [15,16]. The results suggest that when
the CREB level decreased to 1/3 to 1/4 of the original content, the
elevation effect of ZMS on M1 receptor density disappeared.
In addition to the elevation of CREB content, ZMS can also pro-
mote the phosphorylation of CREB. Twelve hours after ZMS addi-
tion, when the CREB content reached its peak, the pCREB content
continued to increase until reaching a peak 24 h after ZMS addition,
implicating the promotion of CREB phosphorylation by ZMS. It is
well known that phosphorylation of CREB is crucial to its activation
[5,6], ultimately involving the establishment and consolidation of
memory [17]. As previously reported [11], ZMS could attenuate
the neurodegenerative process, improving memory in several ani-
mal models by elevating M1 receptor density. It is therefore very
probable that the elevation of M1 receptor density induced by ele-
vation of CREB and pCREB is one of the underlying mechanisms
for the ZMS-mediated memory improvement. Additionally, it
should be pointed out that the up-regulation of M1 receptor density
by CREB relies on the activation of certain kinase(s) and a sufﬁcient
amount (concentration) of CREB. According to the data presented
here, the action of the antisense oligonucleotide is to decrease the
amount of CREB but not to suppress the kinase activity.
ZMS is a sapogenin with a molecular weight of 416. As a rule,
such a small molecule should exert potential actions on gene
expression indirectly through its interaction with other proteins
[18] such as receptors or mediators. We have carried out compet-
itive binding assays with ZMS and many known receptors includ-
ing several G-protein coupled receptors such as various subtypes
of muscarinic, nicotinic, and ionotropic glutamate receptors, as
well as nuclear receptors for oestrogen, progesterone, androgen
and retinoic acid. All of these known receptors could not bind to
ZMS with high afﬁnity, hence they were not acting as efﬁcient
mediators (data not shown).
However, the negative results of such studies did not exclude
the possible action of ZMS on the production or degradation of
these receptors and their ligands. A few years ago, we found that
brain derived neurotrophic factor (BDNF) was decreased in the
brains of aged rats with memory deﬁcits and could be elevated
by ZMS [19]. It is well known that BDNF is important for the devel-
opment, survival, functional activity and synaptic plasticity of neu-
rons [20,21]. It has recently been reported that in several animal
models, as well as in Ab intoxicated cells, BDNF is able to attenuate
the neurodegenerative changes [22,23]. BDNF expression is
coupled to CREB-mediated transcription; thus, when TrkB was
activated by BDNF, the extracellular signal-regulated kinase/mito-
gen-activated protein kinase (ERK/MAPK) pathway was triggered,
promoting the phosphorylation of CREB. Thus, it would be interest-
ing to study the role of BDNF in the activating effect of ZMS on
CREB and M1 receptor density.
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